ABSTRACT
COVID-19 presented countries with unprecedented health policy challenges. For low-income countries in particular, policymakers had to contend with both the direct threats posed by COVID-19 as well as the social, educational, and economic harms associated with lockdown and other infection prevention and control measures. We present a holistic and contextualised case study of the direct and indirect impacts of COVID-19 on women and children, with some assessment of their uneven distribution across socio-economic, age and gender groups. We used different types of primary and secondary data from multiple sources to produce a holistic descriptive analysis. Primary data included: qualitative data obtained from 28 in-depth interviews of key informants, six focus group discussions; and 40 household interviews. We also extracted data from government reports and announcements, the District Health Information Software version 2 (DHIS2), newspaper articles and social media, as well as from published research articles. Our findings show that the direct and indirect adverse impacts of COVID-19 were compounded by many years of severe political economic challenges, and consequent deterioration of the healthcare system. The indirect effects of the pandemic had the most severe impacts on the poorest segment of society and widened age and gender inequalities. The pandemic and its accompanying infection prevention and control measures negatively affected health service delivery and uptake. The management of COVID-19 presented enormous challenges to policymakers and public health specialists. These included managing the greatest tension between direct and indirect harms; short-term and long-term effects; and the unequal distribution of harms across different segments of society.
Competing Interest Statement
SN was one of the health experts working on the ground who called for the lockdowns as he had first-hand information on the healthcare preparedness to face such a new novel coronavirus.
Funding Statement
This work was supported through the Queen Mary University of London (QMUL) with funding from the United Kingdom Research Institute (UKRI) under reference number GCRF_NF391 and implemented through the Organisation of Public Health Interventions and Development (OPHID) Zimbabwe. The views expressed do not necessarily reflect the policies of the respective organisations. The funders had no role in study design, data collection and analysis, the decision to publish, or manuscript preparation. Tinotenda Taruvinga is supported by the Fogarty International Centre of the National Institutes of Health (NIM Bethesda, Maryland, MD, USA) under Award Number D43 TW009539. The content therein is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approvals were obtained from the Medical Research Council of Zimbabwe (MRCZ/2505/A), and the London School of Hygiene and Tropical Medicine (LSHTM) ethics committee (approval number LSHTM Ref 25547). Written informed consent was obtained from all the participants in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Has been updated to include the graphs that were not part of the text and previous document
Data Availability
Data will be made available free access and a DOI will be provided once available. Data is deposited at the London School and Hygiene and Tropical Medicine (LSHTM) data campass
